富祥药业：11月27日召开董事会会议

Group 1 - The core point of the article is that Fuxiang Pharmaceutical announced a board meeting to discuss the authorization for the first phase of the stock option incentive plan [1] - For the year 2024, Fuxiang Pharmaceutical's revenue composition is as follows: 77.94% from pharmaceutical manufacturing, 21.45% from lithium battery electrolyte additives, and 0.61% from CDMO [1] - As of the report, Fuxiang Pharmaceutical has a market capitalization of 8.8 billion yuan [1]